Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prime Medicine, Inc.PRME · Entity 5281 | Director | June 05, 2026 | June 08, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prime Medicine, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.06 · Expires 2036-06-05 | Direct | 75,000 |
Reported balance
After 2026-06-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-05 · Grant · Acquired 75,000 · Balance 75,000 F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Spark Therapeutics, Inc.
Report date December 17, 2019 · Filed December 17, 2019
Section 16 reporting ended · disclosed 2019-12-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 1
1 source rowRow 1 · 2019-12-17 · Other · Disposed 355,215 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.73 · Expires 2029-01-15 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-12-17 · Disposition to issuer · Disposed 98,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $50.55 · Expires 2028-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-12-17 · Disposition to issuer · Disposed 52,500 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $56.17 · Expires 2027-01-17 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-12-17 · Disposition to issuer · Disposed 70,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.44 · Expires 2026-01-04 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-12-17 · Disposition to issuer · Disposed 135,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $68.45 · Expires 2025-03-15 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-12-17 · Disposition to issuer · Disposed 125,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.45 · Expires 2024-07-01 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-12-17 · Disposition to issuer · Disposed 126,131 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-12-17 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2019-12-17 · Disposition to issuer · Disposed 49,250 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn.
F2: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option.
F3: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:20 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $3.06 | $0.00 |
DisclosureSEC source: 0001628280-26-041575 · wk-form4_1780950017.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2036-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 5, 2027 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000048 · wk-form4_1754440996.xml · derivative · entry 6 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 45,000 | Not disclosed Strike: $7.68 | Not disclosed |
DisclosureSEC source: 0001894562-25-000048 · wk-form4_1754440996.xml · derivative · entry 5 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 250,000 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000048 · wk-form4_1754440996.xml · derivative · entry 4 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-02-28 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 250,000 | Not disclosed Strike: $8.63 | Not disclosed |
DisclosureSEC source: 0001894562-25-000048 · wk-form4_1754440996.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2034-02-28 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 92,000 | Not disclosed Strike: $4.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000048 · wk-form4_1754440996.xml · derivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2033-05-10 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| August 01, 2025 Filed Aug 6, 2025 00:43 UTC | Prime Medicine, Inc. PRME · Entity 5281 | Disposition to issuerStock Option (right to buy) · Derivative | 92,000 | Not disclosed Strike: $14.04 | Not disclosed |
DisclosureSEC source: 0001894562-25-000048 · wk-form4_1754440996.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 92,000 shares Expires 2033-05-10 F1 · kind: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F1 · price: Effective as of August 1, 2025 (the "Repricing Date"), the Issuer's stockholders approved a one-time repricing of certain outstanding stock options (the "Repriced Options") granted under the Issuer's 2019 Stock Option and Grant Plan, as amended (the "2019 Plan") and/or the 2022 Stock Option and Incentive Plan (the "2022 Plan" and, together with the 2019 Plan, the "Plans"), which reduced the per share exercise price of each Repriced Option to $4.04, representing the closing price of the Issuer's common stock on The Nasdaq Global Market on the Repricing Date (the "Option Repricing"). Except as modified by the Option Repricing, all other terms and conditions of the Repriced Options, including, without limitation, any provisions with respect to vesting and term of the Repriced Options, remain in full force and effect. F2 · derivative.exercise_date: This stock option award was issued pursuant to the 2019 Plan and/or the 2022 Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date. Read SEC document |
| June 04, 2025 Filed Jun 5, 2025 22:13 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 55,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001628280-25-029773 · wk-form4_1749161395.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-06-04 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 4, 2026 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date. Read SEC document |
| May 19, 2025 Filed May 19, 2025 23:45 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 800,000 | $0.00 Strike: $1.34 | $0.00 |
DisclosureSEC source: 0001894562-25-000024 · wk-form4_1747698326.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,000 Underlying: Common Stock · 800,000 shares Expires not disclosed F1 · derivative.exercise_date: 500,000 of the shares underlying this option shall vest and become exercisable in twenty-four (24) equal monthly installments over a two-year period commencing from May 19, 2025; 300,000 of the shares underlying this option shall vest and become exercisable in three equal installments based on the Issuer's satisfaction of certain performance criteria tied to stock price, in each case subject to the Reporting Person's continued service on each such vesting date. F1 · derivative.expiration_date: 500,000 of the shares underlying this option shall vest and become exercisable in twenty-four (24) equal monthly installments over a two-year period commencing from May 19, 2025; 300,000 of the shares underlying this option shall vest and become exercisable in three equal installments based on the Issuer's satisfaction of certain performance criteria tied to stock price, in each case subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:59 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $7.68 | $0.00 |
DisclosureSEC source: 0001894562-24-000041 · wk-form4_1718398754.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2034-06-12 F1 · derivative.exercise_date: The shares subject to this option shall vest in full upon the earlier of (i) June 12, 2025 or (ii) the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service to the Issuer through such vesting date Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:20 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001894562-24-000018 · wk-form4_1709605211.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The shares underlying this option shall vest in full on the one-year anniversary of the date of grant, subject to the Reporting Person's continued service through such vesting date. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:30 UTC | Prime Medicine, Inc. PRME · Entity 5281 | GrantStock Option (right to buy) · Derivative | 92,000 | $0.00 Strike: $14.04 | $0.00 |
DisclosureSEC source: 0001894562-23-000014 · wf-form4_168392338638014.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,000 Underlying: Common Stock · 92,000 shares Expires 2033-05-10 F1 · derivative.exercise_date: The shares underlying this option shall vest in three equal annual installments beginning on May 10, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerRestricted Stock Units · Derivative | 49,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · derivative · entry 8 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 49,250 shares Expires not disclosed F3 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). F3 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark restricted stock unit, whether vested or unvested, was canceled and converted into the right to receive $114.50 in cash (less applicable tax withholdings). Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 126,131 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · derivative · entry 7 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 126,131 shares Expires 2024-07-01 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $68.45 | $0.00 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · derivative · entry 6 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 125,000 shares Expires 2025-03-15 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $40.44 | $0.00 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · derivative · entry 5 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 135,000 shares Expires 2026-01-04 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 70,000 | $0.00 Strike: $56.17 | $0.00 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · derivative · entry 4 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,000 shares Expires 2027-01-17 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 52,500 | $0.00 Strike: $50.55 | $0.00 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,500 shares Expires 2028-01-17 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Disposition to issuerStock Option (Right to Buy) · Derivative | 98,000 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · derivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 98,000 shares Expires 2029-01-15 F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding Spark stock option, whether vested or unvested, was converted into the right to an amount in cash (less applicable tax withholdings) equal to the product of (a) the excess of $114.50 over the per share exercise price of such stock option and (b) the total number of shares of common stock subject to such stock option. Read SEC document |
| December 17, 2019 Filed Dec 17, 2019 21:44 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | OtherCommon Stock | 355,215 | $114.50 | $40,672,117.50 |
DisclosureSEC source: 0000899243-19-029435 · doc4.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger, dated February 22, 2019, by and between Spark Therapeutics, Inc. ("Spark"), Roche Holdings, Inc. ("Roche") and 022019 Merger Subsidiary, Inc. ("Merger Sub") (the "Merger Agreement" and the transactions contemplated thereby, the "Merger"), whereby Roche caused Merger Sub to conduct a tender offer for all of the issued and outstanding shares of common stock, par value $0.001 per share, of Spark, at a price of $114.50 per share. On December 17, 2019, Merger Sub irrevocably accepted for payment all shares that were validly tendered and not withdrawn. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:26 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 49,940 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0000899243-19-008359 · doc4.xml · derivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,131 Underlying: Common Stock · 49,940 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| March 15, 2019 Filed Mar 19, 2019 21:26 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 49,940 | $3.45 | $172,293.00 |
DisclosureSEC source: 0000899243-19-008359 · doc4.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,215 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 3,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-19-000027 · wf-form4_154828179239879.xml · derivative · entry 6 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,250 Underlying: Common Stock · 3,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F4 · derivative.exercise_date: On January 18, 2018, the reporting person was granted 15,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F4 · derivative.expiration_date: On January 18, 2018, the reporting person was granted 15,000 restricted stock units that vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-19-000027 · wf-form4_154828179239879.xml · derivative · entry 5 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 20,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 20,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 1,174 | $45.08 | $52,923.92 |
DisclosureSEC source: 0001609351-19-000027 · wf-form4_154828179239879.xml · nonDerivative · entry 4 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 305,275 Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 3,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-19-000027 · wf-form4_154828179239879.xml · nonDerivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 306,449 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 1,655 | $45.08 | $74,607.40 |
DisclosureSEC source: 0001609351-19-000027 · wf-form4_154828179239879.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 302,699 Read SEC document |
| January 18, 2019 Filed Jan 23, 2019 22:16 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-19-000027 · wf-form4_154828179239879.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 304,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics, Inc. common stock. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 02:43 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 28,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-19-000012 · wf-form4_154777941873134.xml · derivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutics, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. F3 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 15, 2020. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 15, 2019 Filed Jan 18, 2019 02:43 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 98,000 | $0.00 Strike: $42.73 | $0.00 |
DisclosureSEC source: 0001609351-19-000012 · wf-form4_154777941873134.xml · derivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires 2029-01-15 F1 · derivative.exercise_date: 25% vests January 15, 2020 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:12 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 6,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-19-000002 · wf-form4_154646713319166.xml · derivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 176,071 Underlying: Common Stock · 6,000 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| December 28, 2018 Filed Jan 2, 2019 22:12 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 6,000 | $3.45 | $20,700.00 |
DisclosureSEC source: 0001609351-19-000002 · wf-form4_154646713319166.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 299,354 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionRestricted Stock Units · Derivative | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000014 · wf-form4_151666590117421.xml · derivative · entry 5 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 5,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F5 · derivative.exercise_date: On January 18, 2017, the reporting person was granted 20,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. F5 · derivative.expiration_date: On January 18, 2017, the reporting person was granted 20,000 restricted stock units that vest in four equal annual installments beginning January 18, 2018. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001609351-18-000014 · wf-form4_151666590117421.xml · derivative · entry 4 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Spark Therapeutic common stock. F4 · derivative.exercise_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. F4 · derivative.expiration_date: The restricted stock units vest in four equal annual installments beginning January 18, 2019. Vested shares will be delivered to the reporting person annually on the vesting date. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | GrantEmployee Stock Option (right to buy) · Derivative | 52,500 | $0.00 Strike: $50.55 | $0.00 |
DisclosureSEC source: 0001609351-18-000014 · wf-form4_151666590117421.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,500 Underlying: Common Stock · 52,500 shares Expires 2028-01-17 F2 · derivative.exercise_date: 25% vests January 18, 2019 and the remainder vests in equal annual installments over the following three years. Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Tax withholdingCommon Stock | 1,646 | $50.55 | $83,205.30 |
DisclosureSEC source: 0001609351-18-000014 · wf-form4_151666590117421.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,354 Read SEC document |
| January 18, 2018 Filed Jan 23, 2018 00:05 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 5,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001609351-18-000014 · wf-form4_151666590117421.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 295,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit converted into one share of Spark Therapeutics common stock. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 22:13 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000129 · wf-form4_151380798888443.xml · derivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,071 Underlying: Common Stock · 60,000 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| December 19, 2017 Filed Dec 20, 2017 22:13 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 60,000 | $3.45 | $207,000.00 |
DisclosureSEC source: 0001609351-17-000129 · wf-form4_151380798888443.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 290,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000118 · wf-form4_151061507233228.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,071 Underlying: Common Stock · 20,000 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 20,000 | $71.54 | $1,430,800.00 |
DisclosureSEC source: 0001609351-17-000118 · wf-form4_151061507233228.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $71.33 to $72.00, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 23:18 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 20,000 | $3.45 | $69,000.00 |
DisclosureSEC source: 0001609351-17-000118 · wf-form4_151061507233228.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 22:00 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 21,350 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000096 · wf-form4_150361198717207.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,071 Underlying: Common Stock · 21,350 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 22:00 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 21,350 | $80.01 | $1,708,213.50 |
DisclosureSEC source: 0001609351-17-000096 · wf-form4_150361198717207.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016. The sales reported in this Form 4 included the additional shares that should have sold on August 2, 2017 pursuant to the terms of the Rule 10b5-1 plan, but, because of an administrative error by the third-party administrator of the Rule 10b5-1 plan, were not sold on such date. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.14, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 23, 2017 Filed Aug 24, 2017 22:00 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 21,350 | $3.45 | $73,657.50 |
DisclosureSEC source: 0001609351-17-000096 · wf-form4_150361198717207.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:03 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000092 · wf-form4_150283099786433.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,421 Underlying: Common Stock · 15,000 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:03 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 15,000 | $75.10 | $1,126,500.00 |
DisclosureSEC source: 0001609351-17-000092 · wf-form4_150283099786433.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $74.95 to $75.40, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
| August 11, 2017 Filed Aug 15, 2017 21:03 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionCommon Stock | 15,000 | $3.45 | $51,750.00 |
DisclosureSEC source: 0001609351-17-000092 · wf-form4_150283099786433.xml · nonDerivative · entry 1 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 20:02 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | Exercise / conversionStock Option (right to buy) · Derivative | 28,650 | $0.00 Strike: $3.45 | $0.00 |
DisclosureSEC source: 0001609351-17-000090 · wf-form4_150187693186983.xml · derivative · entry 3 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 298,421 Underlying: Common Stock · 28,650 shares Expires 2024-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on July 2, 2014 and vests over four years, with 25% of the shares underlying the option vesting on May 24, 2015, and the remainder vesting quarterly thereafter. Read SEC document |
| August 02, 2017 Filed Aug 4, 2017 20:02 UTC | Spark Therapeutics, Inc. ONCE · Entity 153045 | SaleCommon Stock | 28,650 | $80.01 | $2,292,286.50 |
DisclosureSEC source: 0001609351-17-000090 · wf-form4_150187693186983.xml · nonDerivative · entry 2 Marrazzo Jeffrey D · CIK 0001631262 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 14, 2016. Due to an administrative error by the third-party administrator of the Rule 10b5-1 plan, not all shares that should have been sold on August 2, 2017 pursuant to the terms of the Rule 10b5-1 plan were sold. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.00 to $80.11, inclusive. The reporting person undertakes to provide to Spark Therapeutics, Inc., any security holder of Spark Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.